UPDATE: Qiagen Cuts Q3 Earnings Forecast Following Terrorist Attacks | GenomeWeb

NEW YORK, Sept. 21 – Qiagen executives on Friday warned  that third-quarter revenues are likely to fall 11 percent to $63 million as a result of disruptions following the Sept. 11 terrorist attacks in the United States.

Qiagen, which manufactures products for nucleic-acid purification, said it now expected to post third-quarter earnings of four cents a share, compared with a previous estimate of seven cents a share, the executives said in a conference call.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.